Expression of NF-kappaB and COX-2 in young versus older patients with sporadic colorectal cancer.

نویسندگان

  • Murdani Abdullah
  • Aru W Sudoyo
  • Bethy S Pranowo
  • Diah Rini
  • Bambang Sutrisna
  • A Aziz Rani
چکیده

AIM To distinguish the expression of NF-kappaB and COX-2 between young and older group of sporadic colorectal cancer patients. METHODS This was a comparative study between sporadic CRC patients aged 40 years or younger and patients aged 60 years or more. Expression of NF-kappaB and COX-2 were assessed by immunohistochemical method using rabbit polyclonal antibodies against human p65 NF-kappaB and COX-2 proteins. RESULTS There were 98 cases of sporadic colorectal cancers between 1999 and 2007 obtained from the Department of Anatomical Pathology, Faculty of Medicine University of Indonesia, Jakarta and Department of Anatomical Pathology, Faculty of Medicine Padjajaran University, Bandung. There were 60 patients aged 60 years or more and 38 patients aged 40 years or less. Most tumors were located in the distal colon. Positive expression of NF-kappaB was found in 72 (73.5%) cases, whereas COX-2 expression was found in 48 (49.0%) cases. No significant difference of NF-kappaB and COX-2 expression between young and older patients. CONCLUSION The expression of nuclear factor kappaB (NF-kappaB) in Indonesian patients with sporadic colorectal cancer was high. However, cyclooxygenase-2 (COX-2) was only expressed in half of patients. There was no significant difference of NF-kappaB and COX-2 expressions between patients aged 40 years or less and patients aged 60 years or more. Further studies are needed to elaborate the role of inflammation in sporadic colorectal carcinogenesis.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Expression of NF-κB and COX-2 in Young Versus Older Patients with Sporadic Colorectal Cancer

Aim: to distinguish the expression of NF-κΒ and COX-2 between young and older group of sporadic colorectal cancer patients. Methods: this was a comparative study between sporadic CRC patients aged 40 years or younger and patients aged 60 years or more. Expression of NF-κΒ and COX-2 were assessed by immunohistochemical method using rabbit polyclonal antibodies against human p65 NFκΒ and COX-2 pr...

متن کامل

The Role of Cyclooxygenase-2 in Signaling Pathways Promoting Colorectal Cancer

Colorectal cancer is one of the most common cancers in the world. Various factors are involved in the development and progression of this disease. One of these agents is cyclooxygenase-2 (COX-2). COX-2 is a product of the PTGS2 gene and converts free arachidonic acid to prostaglandins. COX-2 is not naturally expressed in most normal cells. Noticeably, the increased expression of COX-2 has been ...

متن کامل

Evaluation of Expression of EGFR, HER-2 and COX-2 in Colorectal Cancer

Background and objective: EGFR and HER-2 are two members of ERbB/HER family of Type I Transmembrane growth factor receptors. Cox2 is an enzyme responsible for the conversion of arachidonic acid to prostaglandins, which has a major role in angiogenesis and can modelate tumor growth. The aim of this study was to determine the level of expression of EGFR, HER-2 and Cox2 in colorectd cancer. Mater...

متن کامل

تحلیل بقای بیماران سرطان کولورکتال و عوامل پیش‌آگهی دهنده با استفاده از مدل رگرسیون کاکس

 Background: Colorectal cancer is the third current cancer in the world and the forth cause of death in cancers. Certain factors such as environmental, genetic and life style are related with this cancer. The objective of this study is to find the survival of Iranian patients with colorectal cancer and also to find its prognostic factors. Methods: In this survival study, the data was co...

متن کامل

“How should we treat older patients with Metastatic Colorectal Cancer, A Review”

Nearly 50 % of newly diagnosed colorectal cancer, affect people over 70 years of age. Inclusion of older patients in clinical trials has been extremely rare. As a result, there is debate on how to manage these patients because it is still unclear how to balance the therapeutic advantages and toxicities. For patients who do not have comorbid conditions, with performance status (P.S.) 0–1, treatm...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Acta medica Indonesiana

دوره 41 2  شماره 

صفحات  -

تاریخ انتشار 2009